Stay updated with breaking news from Yu Xia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
China’s National Medical Products Administration has accepted the supplemental new drug application seeking the approval of cadonilimab plus chemotherapy for use in the first-line treatment of patients with unresectable locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.
/PRNewswire/ -- Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA)...
The frontline combination of cadonilimab and platinum-based chemotherapy with or without bevacizumab provided a progression-free survival benefit in patients with recurrent or metastatic cervical cancer.
First-line treatment with the PD-1/CTLA-4 bispecific antibody cadonilimab in combination with oxaliplatin and capecitabine led to a statistically significant improvement in overall survival vs placebo plus oxaliplatin and capecitabine in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, meeting the primary end point of the phase 3 AK104-302 trial.
Several popular television programs in the country are helping to encourage conversations about the social, romantic and sexual needs of older Chinese people.